270 related articles for article (PubMed ID: 38157095)
1. Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis.
Luciano N; Barone E; Timilsina S; Gershwin ME; Selmi C
Clin Rev Allergy Immunol; 2023 Dec; 65(3):403-419. PubMed ID: 38157095
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Nurmohamed MT; van Halm VP; Dijkmans BA
Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
[TBL] [Abstract][Full Text] [Related]
4. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Dixon WG; Symmons DP
Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
[TBL] [Abstract][Full Text] [Related]
5. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
[TBL] [Abstract][Full Text] [Related]
6. The management of cardiovascular disease risk in patients with rheumatoid arthritis.
Ahmed O; Krishnamurthy V; Kaba RA; Tahir H
Expert Opin Pharmacother; 2022 Jun; 23(8):947-958. PubMed ID: 35575484
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
Giollo A; Bissell LA; Buch MH
Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
[TBL] [Abstract][Full Text] [Related]
8. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
Toussirot É
Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.
Barbhaiya M; Solomon DH
Curr Opin Rheumatol; 2013 May; 25(3):317-24. PubMed ID: 23466960
[TBL] [Abstract][Full Text] [Related]
10. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
11. The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature.
Sattin M; Towheed T
Curr Rheumatol Rev; 2016; 12(3):208-222. PubMed ID: 27041084
[TBL] [Abstract][Full Text] [Related]
12. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
Venetsanopoulou AI; Pelechas E; Voulgari PV; Drosos AA
Rheumatol Int; 2020 Aug; 40(8):1181-1191. PubMed ID: 32524301
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Drakopoulou M; Soulaidopoulos S; Oikonomou G; Tousoulis D; Toutouzas K
Curr Vasc Pharmacol; 2020; 18(5):488-506. PubMed ID: 32056527
[TBL] [Abstract][Full Text] [Related]
14. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
Day AL; Singh JA
Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
[TBL] [Abstract][Full Text] [Related]
16. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
[TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
18. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry.
Duruöz MT; Ataman Ş; Bodur H; Çay HF; Melikoğlu MA; Akgül Ö; Çapkın E; Gürer G; Çevik R; Göğüş FN; Kamanlı A; Yurdakul FG; Yağcı İ; Rezvani A; Altan L
Rheumatol Int; 2024 Feb; 44(2):291-301. PubMed ID: 38157014
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).
Mourouzis IS; Manolis AS; Pantos C
Curr Vasc Pharmacol; 2020; 18(5):455-462. PubMed ID: 31566134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]